Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants

Emi Takashita; Seiya Yamayoshi; Viviana Simon; Harm van Bakel; Emilia M. Sordillo; Andrew Pekosz; Shuetsu Fukushi; Tadaki Suzuki; Ken Maeda; Peter Halfmann; Yuko Sakai-Tagawa; Mutsumi Ito; Shinji Watanabe; Masaki Imai; Hideki Hasegawa; Yoshihiro Kawaoka

doi:10.1056/NEJMc2207519

Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants

Emi Takashita
, Seiya Yamayoshi
, Viviana Simon
, Harm van Bakel
, Emilia M. Sordillo
, Andrew Pekosz
, Shuetsu Fukushi
, Tadaki Suzuki
, Ken Maeda
, Peter Halfmann
, Yuko Sakai-Tagawa
, Mutsumi Ito
, Shinji Watanabe
, Masaki Imai
, Hideki Hasegawa
, Yoshihiro Kawaoka

Research output: Contribution to journal › Letter › peer-review

268 Scopus citations

Original language	English
Pages (from-to)	468-470
Number of pages	3
Journal	New England Journal of Medicine
Volume	387
Issue number	5
DOIs	https://doi.org/10.1056/NEJMc2207519
State	Published - 4 Aug 2022

Access to Document

10.1056/NEJMc2207519

Cite this

Takashita, E., Yamayoshi, S., Simon, V., van Bakel, H., Sordillo, E. M., Pekosz, A., Fukushi, S., Suzuki, T., Maeda, K., Halfmann, P., Sakai-Tagawa, Y., Ito, M., Watanabe, S., Imai, M., Hasegawa, H., & Kawaoka, Y. (2022). Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants. New England Journal of Medicine, 387(5), 468-470. https://doi.org/10.1056/NEJMc2207519

@article{71f912ca064841a19f74a0e8d29583f0,

title = "Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants",

author = "Emi Takashita and Seiya Yamayoshi and Viviana Simon and \{van Bakel\}, Harm and Sordillo, \{Emilia M.\} and Andrew Pekosz and Shuetsu Fukushi and Tadaki Suzuki and Ken Maeda and Peter Halfmann and Yuko Sakai-Tagawa and Mutsumi Ito and Shinji Watanabe and Masaki Imai and Hideki Hasegawa and Yoshihiro Kawaoka",

note = "Funding Information: Supported by grants from the Center for Research on Influenza Pathogenesis (HHSN272201400008C, to Dr. Kawaoka) and from the Center for Research on Influenza Pathogenesis and Transmission (75N93021C00014, to Dr. Kawaoka), funded by the National Institutes of Allergy and Infectious Diseases ; and by Research Program on Emerging and Reemerging Infectious Diseases (JP20fk0108412, to Dr. Kawaoka), Project Promoting Support for Drug Discovery (JP21nf0101632, to Dr. Kawaoka), the Japan Program for Infectious Diseases Research and Infrastructure (JP21wm0125002, to Dr. Kawaoka) from the Japan Agency for Medical Research and Development , and a grant-in-aid for Emerging and Reemerging Infectious Diseases from the Ministry of Health, Labor, and Welfare, Japan (20HA2007, to Dr. Hasegawa). ",

year = "2022",

month = aug,

day = "4",

doi = "10.1056/NEJMc2207519",

language = "English",

volume = "387",

pages = "468--470",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "5",

}

Takashita, E, Yamayoshi, S, Simon, V , van Bakel, H , Sordillo, EM, Pekosz, A, Fukushi, S, Suzuki, T, Maeda, K, Halfmann, P, Sakai-Tagawa, Y, Ito, M, Watanabe, S, Imai, M, Hasegawa, H & Kawaoka, Y 2022, 'Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants', New England Journal of Medicine, vol. 387, no. 5, pp. 468-470. https://doi.org/10.1056/NEJMc2207519

TY - JOUR

T1 - Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants

AU - Takashita, Emi

AU - Yamayoshi, Seiya

AU - Simon, Viviana

AU - van Bakel, Harm

AU - Sordillo, Emilia M.

AU - Pekosz, Andrew

AU - Fukushi, Shuetsu

AU - Suzuki, Tadaki

AU - Maeda, Ken

AU - Halfmann, Peter

AU - Sakai-Tagawa, Yuko

AU - Ito, Mutsumi

AU - Watanabe, Shinji

AU - Imai, Masaki

AU - Hasegawa, Hideki

AU - Kawaoka, Yoshihiro

N1 - Funding Information: Supported by grants from the Center for Research on Influenza Pathogenesis (HHSN272201400008C, to Dr. Kawaoka) and from the Center for Research on Influenza Pathogenesis and Transmission (75N93021C00014, to Dr. Kawaoka), funded by the National Institutes of Allergy and Infectious Diseases ; and by Research Program on Emerging and Reemerging Infectious Diseases (JP20fk0108412, to Dr. Kawaoka), Project Promoting Support for Drug Discovery (JP21nf0101632, to Dr. Kawaoka), the Japan Program for Infectious Diseases Research and Infrastructure (JP21wm0125002, to Dr. Kawaoka) from the Japan Agency for Medical Research and Development , and a grant-in-aid for Emerging and Reemerging Infectious Diseases from the Ministry of Health, Labor, and Welfare, Japan (20HA2007, to Dr. Hasegawa).

PY - 2022/8/4

Y1 - 2022/8/4

UR - https://www.scopus.com/pages/publications/85135597425

U2 - 10.1056/NEJMc2207519

DO - 10.1056/NEJMc2207519

M3 - Letter

C2 - 35857646

AN - SCOPUS:85135597425

SN - 0028-4793

VL - 387

SP - 468

EP - 470

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 5

ER -